Drug Search Results
More Filters [+]

Brotizolam

Alternative Names: brotizolam, lendormin, we 941, we-941, we941
Latest Update: 2024-01-01
Latest Update Note: PubMed Publication

Product Description

Brotizolam is a new thienotriazolodiazepine derivative with a pharmacological profile similar to that of benzodiazepines. It is indicated for use as an hypnotic in the management of insomnia, although it also has anticonvulsant, antianxiety and muscle relaxant properties in animals.  (Sourced from: https://pubmed.ncbi.nlm.nih.gov/3281819/)

Mechanisms of Action: GABA Modulator

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Austria | Belgium | Chile | Colombia | Egypt | Germany | Hungary | Ireland | Israel | Italy | Luxembourg | Mexico | Netherlands | Peru | Portugal | South Africa | Spain | Taiwan | Venezuela

Approved Indications: None

Known Adverse Events: None

Company: Boehringer Ingelheim
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Brotizolam

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 4: Depressive Disorder

Phase 3: Insomnia|Dementia|Tic Disorders|Psychophysiologic Disorders|Depressive Disorder|Schizophrenia

Phase 1: Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

GAP

P3

Terminated

Schizophrenia|Depressive Disorder|Tic Disorders|Dementia|Psychophysiologic Disorders

2017-06-28

cs 001-16

P3

Unknown status

Insomnia

2017-04-01

2013-004936-31

P4

Completed

Depressive Disorder

2016-05-28

NCT01361022

P1

Completed

Healthy Volunteers

2011-11-01

Recent News Events